Various aspects of the relationship between vitiligo and the COVID-19 pandemic or SARS-CoV-2 vaccines : Clinical pearls for dermatologists
© 2022 The Authors. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC..
BACKGROUND: Coronavirus disease 2019 (COVID-19) has given rise to several new onset or exacerbated dermatologic disorders including vitiligo.
AIM AND METHOD: Here, we present different aspects of relationship between SARS-CoV-2 infection or its associated vaccines and vitiligo and aim to provide solutions to overcome the potential challenges.
RESULTS AND CONCLUSION: In brief, as the benefits overweigh the risks and since vaccine-triggered de novo or flares of vitiligo are uncommon and benign, these patients are recommended to get SARS-CoV-2 vaccines. Moreover, in individuals with previously recognized vitiligo, who are at risk of developing SARS-CoV-2 infection or those who are currently infected, special dermatologic consultation is needed in order to balance the immunosuppressive agents in their therapeutic regimen to prevent COVID-related morbidity and mortality.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Journal of cosmetic dermatology - 22(2023), 4 vom: 19. Apr., Seite 1152-1156 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aryanian, Zeinab [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biologic agents |
|---|
| Anmerkungen: |
Date Completed 31.03.2023 Date Revised 31.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/jocd.15550 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352721561 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352721561 | ||
| 003 | DE-627 | ||
| 005 | 20231226054354.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/jocd.15550 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1175.xml |
| 035 | |a (DE-627)NLM352721561 | ||
| 035 | |a (NLM)36762373 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Aryanian, Zeinab |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Various aspects of the relationship between vitiligo and the COVID-19 pandemic or SARS-CoV-2 vaccines |b Clinical pearls for dermatologists |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.03.2023 | ||
| 500 | |a Date Revised 31.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 The Authors. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC. | ||
| 520 | |a BACKGROUND: Coronavirus disease 2019 (COVID-19) has given rise to several new onset or exacerbated dermatologic disorders including vitiligo | ||
| 520 | |a AIM AND METHOD: Here, we present different aspects of relationship between SARS-CoV-2 infection or its associated vaccines and vitiligo and aim to provide solutions to overcome the potential challenges | ||
| 520 | |a RESULTS AND CONCLUSION: In brief, as the benefits overweigh the risks and since vaccine-triggered de novo or flares of vitiligo are uncommon and benign, these patients are recommended to get SARS-CoV-2 vaccines. Moreover, in individuals with previously recognized vitiligo, who are at risk of developing SARS-CoV-2 infection or those who are currently infected, special dermatologic consultation is needed in order to balance the immunosuppressive agents in their therapeutic regimen to prevent COVID-related morbidity and mortality | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 vaccine | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a biologic agents | |
| 650 | 4 | |a immunosuppressant agents | |
| 650 | 4 | |a vitiligo | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 700 | 1 | |a Balighi, Kamran |e verfasserin |4 aut | |
| 700 | 1 | |a Hatami, Parvaneh |e verfasserin |4 aut | |
| 700 | 1 | |a Goodarzi, Azadeh |e verfasserin |4 aut | |
| 700 | 1 | |a Janbakhsh, Alireza |e verfasserin |4 aut | |
| 700 | 1 | |a Afshar, Zeinab Mohseni |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cosmetic dermatology |d 2002 |g 22(2023), 4 vom: 19. Apr., Seite 1152-1156 |w (DE-627)NLM166816639 |x 1473-2165 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2023 |g number:4 |g day:19 |g month:04 |g pages:1152-1156 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/jocd.15550 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2023 |e 4 |b 19 |c 04 |h 1152-1156 | ||